PiperJaffray.

Tobacco

Latest Consumer Anecdotes Still Consistent: iQOS and JUUL Stand Out

CONCLUSION

We have been struck by two reduced risk products that appear to stand out so far in terms of consumer traction: iQOS from PMI and JUUL vapor (BAT's glo is promising, too, but does not yet have a track record comparable to iQOS). While we are careful not to extrapolate too much from anecdotes, recent consumer input reminds us that iQOS travels well, and that it likely has more pockets of strength outside Japan than is often appreciated.

- iQOS travels more than one may think: Discovering local users in NYC. We recently
 encountered iQOS users on the streets of Midtown Manhattan. When asked about the
 device, the first 20-something user indicated she purchased it in China and had stocked
 up on HeatSticks to bring back home to New York. A companion indicated that her father
 (in Korea) was a 20 year smoker who recently switched to iQOS. The excitement of the
 group around the product was palpable. A third member of the group proudly volunteered
 that iQOS was popular in Italy, too, where she had discovered it.
- China sales remind us that iQOS travels, likely via Japan. While China is not (yet) an iQOS launch market, we believe sales there (and in Hong Kong we hear about, too) are likely diverted product from Japan. If so, it makes us less concerned about potential trade loading in Asia; we conservatively model 1Q18 volumes, but there could be upside to our estimates if demand is driven in part by diverted sales. While sell-through in Japan remains robust (and growth has yet to slow down), to the extent it may also be a conduit to other markets, we believe momentum in Japan is likely to remain strong.
- Anecdote from Italy suggests pockets of strength. Sales in Italy remain relatively small, with national market share just breaking 1% in 4Q17, but we believe a consumer description of iQOS as popular there is consistent with our view that shares in some areas are much higher (we estimate share in Milan is likely over 5%; chart inside). We believe the product is likely becoming increasingly visible and/or prominent in at least some social circles, given a consumer touting its popularity and its rapid market share acceleration, from 0.7% in 3Q17 to 1.2% in 4Q17 (a ~70% sequential volume increase).
- iQOS and JUUL stand out on adoption rates, growth. We believe current smokers looking to switch to less harmful products are interested in nicotine delivery and taste. We believe the two products with the clearest traction to date are PMI's iQOS and JUUL vapor, a privately held US company that has also faced capacity constraints over the past year and has had ~20% sequential monthly growth rates. Both appear to have compelling nicotine delivery for smokers looking to switch (JUUL's mission is to eradicate smoking, and PMI is 'designing a smoke-free future'), and both have high adoption rates accordingly. Interest (per Google trends, shown inside) has risen sharply for both, too.
- US anecdote: JUUL fulfills a New Year's resolution; taste matters. We recently heard
 from a longtime smoker who paired a New Year's quit-smoking effort with switching to
 JUUL. With some limited dual use, tapering off over time, the effort was successful,
 in part because cigarettes started tasting 'worse and worse.' Armed with just enough
 persistence to use JUUL regularly enough to get acclimated, taste preferences started to
 adjust and the harshness of cigarettes became less and less attractive. PMI has reported
 the same progression for typical iQOS users. (JUUL scanner data chart inside.)

Michael S. Lavery

Sr. Research Analyst, Piper Jaffray & Co. 212 284-9511, michael.s.lavery@pjc.com

Related Companies:	Share Price:
BATS LN	44.40
PM	102.54

Prices as of the close February 14, 2018.

INDUSTRY RISKS

Unfavorable regulatory action, especially disruptive excise tax increases, growth in illicit trade, currency movements, and general macroeconomic erosion.

Piper Jaffray does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decisions. This report should be read in conjunction with important disclosure information, including an attestation under Regulation Analyst certification, found on pages 5 - 7 of this report or at the following site: http://www.piperjaffray.com/researchdisclosures.

Exhibit 1



Source: Google Trends, Piper Jaffray & Co

Similar consumer interest for iQOS and JUUL Google Trends views worldwide interest in real time and indexes the interest of two products against each other. We paired "JUUL" against "iQOS" and found that both have accelerated in a similar pattern over the last couple years, with sharply growing interest in both products.

Exhibit 2

Estimated breakdown of iQOS share trends in Italy

Italy	1Q16	2Q16	3Q16	4Q16	1Q17	2Q17	3Q17	4Q17
National share	0.0%	0.1%	0.1%	0.3%	0.5%	0.6%	0.7%	1.2%
Initial launch area share	0.2%	0.3%	0.5%	1.5%	2.5%	2.8%	3.0%	5.3%
Percent coverage	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%	20.0%
First expansion area share						0.1%	0.2%	0.3%
Percent coverage						44.0%	44.0%	44.0%
Next expansion area share							0.1%	0.2%
Percent coverage							9.0%	9.0%
Total launch area share	0.2%	0.3%	0.5%	1.5%	2.5%	0.9%	1.0%	1.6%
Percent coverage	20.0%	20.0%	20.0%	20.0%	20.0%	64.0%	73.0%	73.0%

Note: We assume expansion area share trends mimic those of the initial launch area's history. Source: Piper Jaffray & Co

Italy likely has initial
launch area share
above 5%Italy's national share rose from 0.5% in 1Q17 to 1.2% in 4Q17, but its footprint grew from 20% of
the country to 73% in 3Q17, which means that it added lots of territory with very little initial share.
(We assume a similar 73% launch area coverage in 4Q17, though PMI has not disclosed an
updated figure.) We estimate its initial launch area share (essentially Milan) grew from 2.5% in
1Q17 to 5.3% in 4Q17, reflecting more strong momentum locally than its national share suggests.
On the following page, we compare this progression to other launch area share of ~0.5% is similar
across many launch areas worldwide.

Exhibit 3



iQOS share trend comparisons, Japan cities vs. initial launch areas in European markets

Note: Key cities are used to identify initial launch areas which can include other cities. Source: Piper Jaffray & Co

Launch area trends point to promising potential

Launch area share trajectories closely mirror - or exceed - Japan's trends, if using the first quarter with a ~0.5% market share as a starting point for comparison. We consider this starting point to be relevant as it reflects sufficient local awareness. Using that quarter as 'quarter one' and then each following quarter as 'quarter two', etc., we see faster relative momentum in Athens, Bucharest and Lisbon than we saw in Nagoya and Tokyo. Athens reached 0.5% in its launch quarter and only has five periods since of history since launching.



Source: IRI, Piper Jaffray & Co

JUUL retail sales soar in 2017

JUUL's 4-week sales growth grew over 800% in 2017, with under \$5M in sales during the 4 weeks ending mid-February 2017 and over \$46M in the 4 weeks ended mid-January 2018.



British American Tobacco (BATS- LON)	We rate BATS LN Overweight. Our target price of £61 applies a ~17.5x multiple to our 2019E EPS of £3.50. We expect BATS to deliver 8-9% three-year average organic sales growth and 12-13% average EPS growth. Risks: Disruptive excise taxes, macro pressure, and currency moves may pose risks to profits.
Philip Morris International (PMI)	We rate PM Overweight. Our target price of \$126 applies a ~22x multiple to our 2019E EPS of \$5.75. We expect PMI to deliver 8-9% three-year average organic sales growth and 11-12% average EPS growth. Risks: Unfavorable regulatory action, especially disruptive excise tax increases, a stronger US dollar and the growth of counterfeit products could pose a risk to upside to the shares.

IMPORTANT RESEARCH DISCLOSURES



Notes: The boxes on the Rating and Price Target History chart above indicate the date of the fundamental Equity Research Note, the rating and the price target. Each box represents a date on which an analyst made a change to a rating or price target, except for the first box, which may only represent the first Note written during the past three years.

Legend:

- I: Initiating Coverage
- R: Resuming Coverage
- T: Transferring Coverage
- D: Discontinuing Coverage
- S: Suspending Coverage OW: Overweight
- N: Neutral
- UW: Underweight
- NA: Not Available
- UR: Under Review

Distribution of Ratings/IB Services Piper Jaffray							
			IB Serv./Past 12 Mos.				
Rating	Count	Percent	Count	Percent			
BUY [OW]	383	57.42	102	26.63			
HOLD [N]	264	39.58	24	9.09			
SELL [UW]	20	3.00	0	0.00			

PiperJaffray.

Note: Distribution of Ratings/IB Services shows the number of companies currently covered by fundamental equity research in each rating category from which Piper Jaffray and its affiliates received compensation for investment banking services within the past 12 months. FINRA rules require disclosure of which ratings most closely correspond with "buy," "hold," and "sell" recommendations. Piper Jaffray ratings are not the equivalent of buy, hold or sell, but instead represent recommended relative weightings. Nevertheless, Overweight corresponds most closely with buy, Neutral with hold and Underweight with sell. See Stock Rating definitions below.

Analyst Certification — Michael S. Lavery, Sr. Research Analyst

The views expressed in this report accurately reflect my personal views about the subject company and the subject security. In addition, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this report.

Piper Jaffray research analysts receive compensation that is based, in part, on overall firm revenues, which include investment banking revenues.

Time of dissemination: 14 February 2018 22:42EST.

Research Disclosures

Piper Jaffray usually provides bids and offers for the securities of British American Tobacco plc and will, from time to time, buy and sell British American Tobacco plc securities on a principal basis.

Piper Jaffray was making a market in the securities of Philip Morris International Inc. at the time this research report was published. Piper Jaffray will buy and sell Philip Morris International Inc. securities on a principal basis.

Affiliate disclosures: Piper Jaffray is the trade name and registered trademark under which the corporate and investment banking products and services of Piper Jaffray Companies and its subsidiaries Piper Jaffray & Co. and Piper Jaffray Ltd. are marketed. Simmons & Company International is a division of Piper Jaffray & Co. This report has been prepared by Piper Jaffray & Co. and/or its affiliate Piper Jaffray Ltd. Piper Jaffray & Co. is regulated by FINRA, NYSE and the United States Securities and Exchange Commission, and its headquarters are located at 800 Nicollet Mall, Minneapolis, MN 55402. Piper Jaffray Ltd. is authorized and regulated by the Financial Conduct Authority, and is located at 88 Wood Street, 13th Floor, London EC2V 7RS. Disclosures in this section and in the Other Important Information section referencing Piper Jaffray include all affiliated entities unless otherwise specified.

Rating Definitions

Stock Ratings: Piper Jaffray ratings are indicators of expected total return (price appreciation plus dividend) within the next 12 months. At times analysts may specify a different investment horizon or may include additional investment time horizons for specific stocks. Stock performance is measured relative to the group of stocks covered by each analyst. Lists of the stocks covered by each are available at www.piperjaffray.com/researchdisclosures. Stock ratings and/or stock coverage may be suspended from time to time in the event that there is no active analyst opinion or analyst coverage, but the opinion or coverage is expected to resume. Research reports and ratings should not be relied upon as individual investment advice. As always, an investor's decision to buy or sell a security must depend on individual circumstances, including existing holdings, time horizons and risk tolerance. Piper Jaffray sales and trading personnel may provide written or oral commentary, trade ideas, or other information about a particular stock to clients or internal trading desks reflecting different opinions than those expressed by the research analyst. In addition, Piper Jaffray offers technical and event-driven research products that are based on different methodologies, may contradict the opinions contained in fundamental research reports, and could impact the price of the subject security. Recommendations based on technical or event-driven analysis are intended for the professional trader, while fundamental opinions are typically suited for the longer-term institutional investor.

- Overweight (OW): Anticipated to outperform relative to the median of the group of stocks covered by the analyst.
- Neutral (N): Anticipated to perform in line relative to the median of the group of stocks covered by the analyst.
- Underweight (UW): Anticipated to underperform relative to the median of the group of stocks covered by the analyst.

Other Important Information

The material regarding the subject company is based on data obtained from sources we deem to be reliable; it is not guaranteed as to accuracy and does not purport to be complete. This report is solely for informational purposes and is not intended to be used as the primary basis of investment decisions. Piper Jaffray has not assessed the suitability of the subject company for any person. Because of individual client requirements, it is not, and it should not be construed as, advice designed to meet the particular investment needs of any investor. This report is not an offer or the solicitation of an offer to sell or buy any security. Unless otherwise noted, the price of a security mentioned in this report is the market closing price as of the end of the prior business day. Piper Jaffray does not maintain a predetermined schedule for publication of research and will not necessarily update this report. Piper Jaffray policy generally prohibits research analysts from sending draft research reports to subject company is have discussions with the subject company to ensure factual accuracy prior to publication, and has had assistance from the company in conducting diligence, including visits to company sites and meetings with company management and other representatives.

Notice to customers: This material is not directed to, or intended for distribution to or use by, any person or entity if Piper Jaffray is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to such person or entity. Customers in any of the jurisdictions where Piper Jaffray and its affiliates do business who wish to effect a transaction in the securities discussed in this report should contact their local Piper Jaffray representative, or as otherwise noted below. **Canada:** This research report is distributed in Canada by CIBC World Markets Inc. Investors in Canada wishing to effect a transaction in the securities discussed in this report should contact their local Piper Jaffray representative, or as otherwise noted below. **Canada:** This research report is distributed in Canada by CIBC World Markets Inc. Investors in Canada wishing to effect a transaction in the securities discussed in this report should contact their CIBC sales representative. This research report has not been prepared in accordance with the disclosure requirements of Dealer Member Rule 3400 – Research Restrictions and Disclosure Requirements of the Investment Industry Regulatory Organization of Canada. For further disclosure related to CIBC conflicts of interest please visit https://research.central.cibcwm.com. **Europe:** This material is for the use of intended recipients only and only for distribution to professional and institutional investors, i.e. persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom, or persons who have been categorised by Piper Jaffray & Co., member SIPC, FINRA and NYSE, Inc., which accepts responsibility for its contents. The securities described in this report may not have been registered under the U.S. Securities Act of 1933 and, in such case, may not be offered or sold in the United States or to U.S. persons unless they have been so registered, or an exemption from the registra

This report is produced for the use of Piper Jaffray customers and may not be reproduced, re-distributed or passed to any other person or published in whole or in part for any purpose without the prior consent of Piper Jaffray & Co. Additional information is available upon request. Copyright 2018 Piper Jaffray. All rights reserved.